TABLE 1.
Description of expected effect of mutation used | Sos variant presenta | Ras variant added | Measured Kd |
---|---|---|---|
μm | |||
None | SosCat | H-Ras·GDP | 54 ± 4 |
None | SosCat | H-Ras·GTPγS | 5.0 ± 0.8 |
None | SosCat | H-Ras·GppNp | 6.0 ± 0.9 |
None | SosCat | H-Ras·GppCp | 8.0 ± 1.0 |
Is not expected to bind at catalytic site | SosCat | H-RasY64A·GTPγS | 10 ± 1 |
Binding expected to be hindered at allosteric site | SosCatW729E | H-Ras·GTPγS | 28 ± 1 |
Binding expected to be hindered at allosteric site | SosHD-DH-PH-Cat | H-Ras·GTPγS | 24 ± 2 |
Binding expected to be hindered at both sites of Sos | SosCatW729E | H-RasY64A·GTPγS | 32 ± 3 |
Binding expected to be hindered at allosteric site | SosCatW729E | H-Ras·GDP | 67 ± 2 |
H-RasY64A·GTPγS expected to partially saturate allosteric site | SosCat (preloaded with 30 μm H-RasY64A·GTPγS) | H-Ras·GTPγS | 21 ± 2b |
None | SosCat | K-Ras·GTPγS | 10 ± 1 |
Oncogenic variant | SosCat | K-RasG12V·GTPγS | 31 ± 2 |
a Unless stated otherwise, the WT version of protein was used.
b Lower limit estimate.